Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 3/20 | 0.41 |
| ▸ | HMGCR | P04035 | 5/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PDE6D | O43924 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17875116 | 0.87 | ADORA1 (0.41) | ADORA1SCN9AGCGRHMGCRHDAC1 | |
| SCHEMBL1785167 | 0.84 | GCGR (0.40) | GCGRHMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL8241631 | 0.82 | GCGR (0.44) | GCGRHMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL7920443 | 0.81 | GCGR (0.43) | GCGRHMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL27850982 | 0.81 | GCGR (0.43) | GCGRHMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL527760 | 0.80 | ADORA1 (0.49) | ADORA1SCN9AGCGR | |
| SCHEMBL2340032 | 0.79 | ADORA1 (0.48) | ADORA1SCN9AGCGR | |
| SCHEMBL2340089 | 0.79 | ADORA1 (0.48) | ADORA1SCN9AGCGR | |
| SCHEMBL2344474 | 0.79 | ADORA1 (0.48) | ADORA1SCN9AGCGR | |
| SCHEMBL27633941 | 0.79 | ADORA1 (0.43) | ADORA1SCN9AGCGRHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116178280-A | Preparation method of rosuvastatin calcium genotoxic impurity | 浙江乐普药业股份有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-116178280-A | Preparation method of rosuvastatin calcium genotoxic impurity | 浙江乐普药业股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116178280-A | Preparation method of rosuvastatin calcium genotoxic impurity | 浙江乐普药业股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-2598484-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2016-06-29 | — | — | EP | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| EP-2423195-A1 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012013325-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-02 | — | — | WO | disclosed |
| US-20110295005-A1 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES | RATIOPHARM GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110295005-A1 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES | RATIOPHARM GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110295005-A1 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES | RATIOPHARM GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-2178847-A2 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES | Ratiopharm GmbH (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009024323-A2 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES | RATIOPHARM GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024323-A2 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES | RATIOPHARM GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2007074391-A2 | PREPARATION OF A KEY INTERMEDIATE IN THE SYNTHESIS OF ROSUVASTATIN | KHAMAR BAKULESH MAFATLAL (IN) | 2007-07-05 | — | — | WO | disclosed |
| US-RE37314-E1 | Pyrimidine derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | disclosed |
| US-5260440-A | Anticholesterol agents | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-11-09 | — | — | US | disclosed |
| EP-0521471-A1 | Pyrimidine derivatives as HMG-CoA reductase inhibitors | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, PCSK9, FAH | ADORA1 2992/4885SCN9A 4346/4885GCGR 2328/4885 |
| US-20110295005-A1 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES | HMGCR, DPYD, FDPS | ADORA1 1072/4885SCN9A 4303/4885GCGR 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.